Pharmacological methods to overcome IFN-β antibody formation in the treatment of multiple sclerosis

Bibliography

• JACOBS LD, BECK RW, SIMON JH et al.: Intramuscular interferon 13-1 a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl. J. Med. (2000) 343(13):898–904.
   PubMed Web of Science ®Google Scholar
• COMI G, FILIPPI M, BARKHOF F et al.: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 357(9268):1576–1582.
   PubMed Web of Science ®Google Scholar
• JACOBS LD, COOKFAIR DL, RUDICK RA et al.: Intramuscular interferon 13 la for disease progression in relapsing-remitting multiple sclerosis. Ann. Neurol (1996) 39(3):285–294.
   PubMed Web of Science ®Google Scholar
• POZZILLI C, BASTIANELLO S, KOUDRAIVTSEVA T et al.: Magnetic resonance imaging changes with recombinant human interferon-13-1a: a short-term study in relapsing-remitting multiple sclerosis.' Neurol Neurosurg. Psychiatry (1996) 61(3):251–258.
   Google Scholar
• THE PRISMS STUDY GROUP, THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: PRISMS-4: Long-term efficacy of interferon-I3-1a in relapsing MS. Neurology (2001) 56(12):1628–1636.
   PubMed Web of Science ®Google Scholar
• PANITCH H, GOODIN DS, FRANCIS G et al.: Randomized, comparative study of interferon b-la treatment regimen in MS: The EVIDENCE Trial. Neurology (2002) 59(10):1496–1506.
   PubMed Web of Science ®Google Scholar
• DURELLI L, VERDUN E, BARBERO P et al.: Every-other-day interferon I3-lb versus once-weekly interferon I3-la for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet (2002) 359(9316):1453–1460.
   PubMed Web of Science ®Google Scholar
• KNOBLER RL, GREENSTEIN JI, JOHNSON KP et al: Systemic recombinant human interferon-I3 treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J. Interferon Cytokine Res. (1993) 13(5):333–340.
   Web of Science ®Google Scholar
• THE IFNB MULTIPLE SCLEROSIS GROUP, THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: Interferon 13-lb in the treatment of multiple sclerosis. Final outcome of the randomised controlled trial. Neurology (1995) 45(7):1277–1285.
   PubMed Web of Science ®Google Scholar
• SPECTRIMS STUDY GROUP: Randomized controlled trial of interferon 13-1 a in secondary progressive MS. Neurology (2001) 56(11):1496–1504.
   PubMed Web of Science ®Google Scholar
• LI DK, ZHAO GJ, PATY DW: Randomized controlled trial of interferon-13- la in secondary progressive MS: MRI results. Neurology (2001) 56(11):1505–1513.
   PubMed Web of Science ®Google Scholar
• EUROPEAN STUDY ON INTERFERON BETA-1B IN SECONDARY-PROGRESSIVE MS: Placebo-controlled multicentre randomised trial of interferon I3-lb in treatment ofsecondary progressive multiple sclerosis. Lancet (1998) 352(9139):1491–1497.
   PubMed Web of Science ®Google Scholar
• LEARY SM, MILLER DH, STEVENSONV VL, BREX PA, CHARD DT, THOMPSON AJ: Interferon 13-la in primary-progressive MS: An exploratory, randomized, controlled trial. Neurology (2003) 60(1):44–51.
   PubMed Web of Science ®Google Scholar
• THE IFNB MULTIPLE SCLEROSIS GROUP, THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: Neutralizing antibodies during treatment of multiple sclerosis with interferon 13-lb: Experience during the first three years. Neurology (1996) 47(4):889–894.
   PubMed Web of Science ®Google Scholar
• ABDUL-AHAD AK, GALAZKA AR, REVEL M, BIFFONI M, BORDEN EC: Incidence of antibodies to interferon-b in patients treated with recombinant human interferon b-bla from mammalian cells. Cytokines Cell. Mol .Ther: (1997) 3(1):27–32.
   PubMedGoogle Scholar
• KIVISAKK P, ALM GV, TAIN WZ, MATUSEVICIUS D, FREDRIKSON S, LINK H: Neutralizing and binding anti-interferon-b- lb (RIFNB- lb) antibodies during RIFNB- lb treatment in multiple sclerosis. Multiple Sclerosis (1997) 3(3):184–190.
   PubMed Web of Science ®Google Scholar
• ANTONELLI G, BAGNATO F, POZZILLI C et al.: Development of neutralizing antibodies in patients with multiple sclerosis treated with IFN-b la. Inteferon Cytokine Res. (1998) 18(5):345–350.
   PubMed Web of Science ®Google Scholar
• ROSS C, CLEMMESEN KM, SVENSON M et al.: Immunogenicity of interferon-I3 in multiple sclerosis patients: influence of preparation, dosage, dose, frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann. Neurol (2000) 48(5):706–712.
   Google Scholar
• SCAGNOLARI C, BELLOMI F, TURRIZIANI 0 et al.: Neutralizing and binding antibodies to IFN-B: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-B preparations. I Inteferon Cytokine Res. (2002) 22(2):207–213.
   Google Scholar
• PERINI P, FACCHINETT A, BULIAN P et al.: Interferon-I3 (IFN-I3) antibodies in interferon-I3-1 a and interferon-I3- lb-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-I3-immunogenicity in vivo. Ear: Cytokine Newt. (2001) 12(1):56–61.
   Google Scholar
• PUNGOR E, FILES JG, GABE JD et al.: A novel bioassay for the determination of neutralizing antibodies to IFN-131b. 1 Interferon Cytokine Res. (1998) 18(12):1025–1030.
   Google Scholar
• FERNANDEZ 0, MAYORGA C, LUQUE G et al.: Study of binding and neutralizing antibodies to interferon-I3 in two groups of relapsing-remitting multiple sclerosis patients. J. Nemo]. (2001) 248(5):383–388.
   Google Scholar
• DEISENHAMMER F, REINDL M, HARVEY J, GASSE T, DILTZE, BERGER T: Bioavailability of interferon 13 lb in MS patients with and without neutralizing antibodies. Neurology (1999) 52(6):1239–1243.
   PubMed Web of Science ®Google Scholar
• ZANG YC, YANG D, HONG J, TEJADA-SIMON MV, RIVERA VM, ZHANG JZ: Immunoregulation and blocking antibodies induced by interferon l3 treatment in MS. Neurology (2000) 55(3):397–404.
   PubMed Web of Science ®Google Scholar
• PERINI P, WADHWA M, BUTTARELLO M et al: Effect of IFNI3 and anti-IFNI3 antibodies on NK cells in multiple sclerosis patients. Neuroimmunol (2000) 105(1):91–95.
   Google Scholar
• RUDICK RA, SIMONIAN NA, ALAM JA et al.: Incidence and significance of neutralizing antibodies to interferon 13-1 a in multiple sclerosis. Neurology (1998) 50(5):1226–1272.
   Web of Science ®Google Scholar
• RICE GPA, PASZNER B, OGER J, LESAUX RN, PATY D, EBERS G: The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferonI3- lb. Neurology (1999) 52(6):1277–1279.
   PubMed Web of Science ®Google Scholar
• POLMAN C, KAPPOS L, WHITE R et al.: Neutralizing antibodies during treatment of secondary progressive MS with interferon 13-1b. Neurology(2003) 60(1):37–43.
   PubMed Web of Science ®Google Scholar
• •A complete and detailed analysis of the clinical relevancies of NAbs, either in a cross-sectional or in a longitudinal evaluation.
   Google Scholar
• PETKAU J, WHITE R: Neutralizing antibodies and the efficacy of interferon 13-lb in relapsing-remitting multiple sclerosis. Mult. Scler: (1997) 3(6):402.
   PubMed Web of Science ®Google Scholar
• ARNASON BG, DIANZANI F: Correlation of the appearance of anti-interferon antibodies during treatment and diminution of efficacy: Summary of an international workshop on anti-interferon antibodies.' Interferon Cytokine Res. (1998) 18(8):639–644.
   PubMedGoogle Scholar
• PRISMS STUDY GROUP. Randomised double-blind placebo-controlled study of interferonl3- la in relapsing/remitting multiple sclerosis. Lancet (1998) 352(9139):1498–1504.
   PubMed Web of Science ®Google Scholar
• CLANET M, RADUE EW, KAPPOS L et al.: A randomized double blind, dose-comparison study of weekly interferonB-1 a in relapsing MS. Neurology (2002) 59(10):1507–1517.
   PubMed Web of Science ®Google Scholar
• COOK SD, QUINLESS JR, JIOTKWITZ A, BEATON P: Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology (2001) 57(6):1080–1084.
   PubMed Web of Science ®Google Scholar
• VALLITTU AM, HALMINEN M, PELTONIEMI J et al.: Neutralizing antibodies reduce MxA protein induction in interferon-I3- la-treated MS patients. Neurology(2002) 58(12):1786–1790.
   PubMed Web of Science ®Google Scholar
• RONNI T, MELEN K, MALYGIN A, JULKUNEN I: Control of IFN-inducible MxA gene expression in human cells. Immunol (1993) 150(5):1715–1726.
   Web of Science ®Google Scholar
• The Molecular Biology of Cytokines. T Megaer (Ed.), John Wiley & Sons Ltd (1998):175.
   Google Scholar
• ••An extremely valuable textbook onmechanism of actions, biological meaning and genetics of cytokines.
   Google Scholar
• WEJSTAL R, NORKRANS G, WEILAND 0 et al.: Lymphocyte subsets and I32-microglobulin expression in chronic hepatitis C/non-A, non-B. Effect of interferon-alpha treatment. Clin. Exp. Immunol (1992) 87:340–345.
   Google Scholar
• GREY H, KUBO RT, COLON SM et al.: The small subunit of HLA antigens in 132 microglobulin. Exp. Med. (1973) 138(6):1608–1610.
   PubMed Web of Science ®Google Scholar
• DE MAYER E, DE MAYER- GIUGNARD J: The Interferon Gene Family Interferons and Other Regulatory Cytokines. Wiley Interscience, New York (1998):5–38.
   Google Scholar
• FUCHS D, WEISS G, REIBNEGGER G, WATECHER H: The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Grit. Rev Clin. Lab. Sci. (1992) 29(3-4):307–341.
   PubMed Web of Science ®Google Scholar
• KHADEMI M, WALLSTROM E, ANDERSSON M et al.: Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon 13-la treatment of multiple sclerosis. Neuroimmunol (2000) 103(2):202–210.
   Google Scholar
• KRACKE A, VON WUSSOV P, AL-MASRI AN, DALLEY G, WINDHAGEN A, HEIDENREICH F: Mx proteins in blood leukocytes for monitoring interferon 13-lb therapy in patients with MS. Neurology (2000) 54(1):193–199.
   PubMed Web of Science ®Google Scholar
• WILLIAMS GJ, WITT PL: Comparative study of the pharmacodynamic and pharmacological effects of Betaseron and Avonex..1. Interferon Cytokine Res. (1998) 18(11):967–975.
   Google Scholar
• CHIANG J, GLOFF CA, YOSHIZAWA CN, WILLIAMS GJ: Pharmacokinetics of recombinant human interferon-I3 volunteers and its effect on serum neopterin. Phann. Res. (1993) 10(4):567–572.
   PubMed Web of Science ®Google Scholar
• MUNAFO A, TRINCHARD-LUGAN I, NGUYEN TXQ, BURAGLIO M: Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon 13-la after intramuscular and subcutaneous administration. Eurj Neurol (1998) 5(2):187–193.
   Web of Science ®Google Scholar
• ROTHUIZEN LE, BUCLIN T, SPERTINI F et al.: Influence of Interferon 13-la dose frequency on PBMC cytokine secretion and biological effect markers. Neuroimmunol (1999) 99(1):131–141.
   Google Scholar
• ALAM J, GOELZ S, RIOUX P et al.: Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon 13-la (IFNI3-1a) products administered intramuscularly in healthy male and female volunteers. Pharm. Res. (1997) 14(14):546–549.
   PubMed Web of Science ®Google Scholar
• STURZEBECHER S, MAIBAUER R, HEUNER A, BECKMANN K, AUFDEMBRINKE B: Pharmacodynamic comparison of single doses of IFN-131a and IFN-131b in healthy volunteers.' Interferon Cytokine Res. (1999) 19(11):1257–1264.
   PubMed Web of Science ®Google Scholar
• BAGNATO F, POZZILLI C, SCAGNOLARI C et al.: A one-year study on the pharmacodynamic profile of interferon 13-la in multiple sclerosis. Neurology (2002) 58(9):1409–1411.
   PubMed Web of Science ®Google Scholar
• DEISENHAMMER F, MAYRINGER I, HAREVY J et al.: A comparative study of the relative bioavailability of different interferon 13 preparations. Neurology (2000) 54(11):2055–2060.
   PubMed Web of Science ®Google Scholar
• THE MUSCLE STUDY GROUP: Randomized pilot trial of I3INF1a (Avonex) in patients with inclusion body myositis. Neurology (2001) 57(9):1566–1570.
   PubMed Web of Science ®Google Scholar
• FIERLBECK G, ULMER A, SCHREINER T, STROEBEL W, SCHIEBEL U, BRZOSKA J: Pharmacodynamics of recombinant IFN-13 during long-term treatment of malignant melanoma.' Interferon Cytokine Res. (1996) 16(10):777–781.
   PubMed Web of Science ®Google Scholar
• ZIPP F, WELLER M, CALABRESI PA et al.: Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann. Neurol (1998) 43(1):116–120.
   PubMed Web of Science ®Google Scholar
• KASTRUKOFF LF, MORGAN NG, ZECCHINI D et al.: Natural killer cells in relapsing-remitting MS: effect of treatment with interferon 13-1B. Neurology (1999) 52(2):351–359.
   PubMed Web of Science ®Google Scholar
• Roitt's Essential Immunology (9th Ed.). IM Roitt (Ed.), Blackwell Science Ltd, Oxford, England (1997):168–177.
   Google Scholar
• LASSMANN H: The pathology of multiple sclerosis and its evolution. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (1999) 354(1390):1635–1640.
   PubMed Web of Science ®Google Scholar
• LUCCHINETTI C, BRUCK W, PARISI J, SCHEITHAUER B, RODRIGUEZ M, LASSMANN H: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol (2000) 47(6):707–717.
   PubMed Web of Science ®Google Scholar
• ••An original and very useful study ondifferences of pathology of a given CELs in MS.
   Google Scholar
• PRINEAS JW, WRIGHT RG: Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab. Invest. (1978) 38(4):409–421.
   PubMed Web of Science ®Google Scholar
• ARCHELOS JJ, STORCH MK, HARTUNG HP: The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol (2000) 47(6):694–706.
   PubMed Web of Science ®Google Scholar
• ESIRI MM: Immunoglobulin-containing cells in multiple-sclerosis plaques. Lancet (1977) 2(8036):478–480.
   PubMed Web of Science ®Google Scholar
• OZAWA K, SUCHANEK G, BREITSCOPF H et al.: Patterns of oligodendroglia pathology in multiple sclerosis. Brain (1994) 117\(Part 6):1311–1322.
   Google Scholar
• OEGERJ, VOREBEYCHICK G, PATY DW: In betaseron treated MS patients, in vivo immune function can be a predictor of neutralising antibody development. Neurology (1997) 48(4):A80.
   Google Scholar
• ZIVADINOV R, RUDICK RA, DE MAST R et al.: Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology (2001) 57(7):1239–1247.
   Google Scholar
• GOODKIN DE, KINKEL RP, WEINSTOCK-GUTTMANN B et al: A Phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology (1998) 51(1):239–245.
   Google Scholar
• GASPERINI C, POZZILLI C, BASTIANELLO S et al.: Effects of steroids on Gd-enhancing lesions before and during recombinant 13 interferon la treatment in relapsing remitting multiple sclerosis. Neurology (1998) 50(2):403–406.
   PubMed Web of Science ®Google Scholar
• RICHERT ND, OSTUNI JL, BASH CN, LEIST TP, MCFARLAND HF, FRANK JA: Interferon I3-lb and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Malt. Scler. (2001) 7(1):49–58.
   PubMed Web of Science ®Google Scholar
• ROSENBERG GA, DENCOFF JE, CORREA N Jr, REINERS M, FORD CC: Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology (1996) 46(6):1626–1632.
   PubMed Web of Science ®Google Scholar
• ALAMAWI WY, BEYHUM HN, RAHME AA, RIEDER MJ: Regulation of cytokine and cytokine receptor expression by glucocorticoids. Leukoc. Biol. (1996) 60(5):563–572.
   PubMed Web of Science ®Google Scholar
• POZZILLI C, ANTONINI G, BAGNATO F et al.: Monthly corticosteroids decrease neutralizing antibodies to RIFN131 b: a randomized trial in multiple sclerosis. Neurol (2002) 249(1):50–56.
   Web of Science ®Google Scholar
• WHO: WHO Expert Committee On Biological Standardisation. Thirty-fifth report. WHO Technical Report Series 725. World Health Organisation, Geneva, Switzerland (1985).
   Google Scholar
• HRICIK DE, ALMAWI WJ, STROM TB: Trends in the use of glucocorticoids in renal transplantation. Transplantation (1994) 57(7)979–989.
   Google Scholar
• ROLAK LA, HARATI Y: Neuroinnnunology for the Clinicians. Butterworth-Heinemann, Newton, MA, USA (1998).
   Google Scholar
• CALABRESI PA, WILETRDINK JL, ROGG JM, MILLS P, WEBB A, WHARTENBY KA: An open-label trial of combination therapy with interferon I3-la and oral methotrexate in MS. Neurology (2002) 58(2):314–317.
   PubMed Web of Science ®Google Scholar
• PATTI F, CATALDI DI ML, NICOLETTI F, REGGIO E, NICOLETTI A, REGGIO A: Combination of cyclophosphamide and interferon-I3 halts progression in patients with rapidly transitional multiple sclerosis. I Neuro/. Neurosurg. Psychiatry (2001) 71(3)404–407.
   Google Scholar
• FERNANDEZ 0, GUERRERO M, MAYORGA C et al.: Combination therapy with interferon I3-lb and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study. Neurol (2002) 249(8):1058–1062.
   Google Scholar
• SALMAGGI A, CORSINI E, LA MANTIA L et al.: Immunological monitoring of azathioprine treatment in multiple sclerosis patients. Neurol (1997) 244(3):167–174.
   Google Scholar
• RINKARDT NE, KRUTH SA, KAUSHIK A: The effects of prednisone and azathioprine on circulating immunoglobulin levels and lymphocyte subpopulations in normal dogs. Can. I Vet. Res. (1999) 63(1):18–24.
   PubMed Web of Science ®Google Scholar
• KHAN OA, DHIB-JALBUT SS: Neutralizing antibodies to interferon 13-la and interferon I3-lb are cross-reactive. Neurology (1998) 51(6):1698–1702.
   PubMed Web of Science ®Google Scholar
• ANTONELLI G, SIMEONI E, BAGNATO F et al.: Further study on the specificity and the incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN 13-la or IFNNeurol Sci. (1999) 168(2):131–136.
   Google Scholar
• BERTOLOTTO A, MALUCCHI S, MILANO E, CASTELLO A, CAPOBIANCO M, MUTANI N: Interferon 13 neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Innnunophannacology (2000) 48(2):95–100.
   PubMed Web of Science ®Google Scholar
• KIVISAKK P, ALM GV, FREDRIKSON S, LINK H: Neutralizing and binding anti-interferon-I3 (IFN-13) antibodies. A comparison between IFN-13-la and IFN-13-lb treatment in multiple sclerosis. Ear. Neurol (2000) 7(1):27–34.
   Google Scholar
• DRESSER DW, MITCHISON NA: The mechanism of immunological paralysis. Adv. Innnunol (1968) 8:129–181.
   PubMedGoogle Scholar
• BERTOLOTTO A, MALUCCHI S, SALA A et al.: Differential effects of three interferon Bs on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. j Neuro/. Neurosurg. Psychiatry (2002) 73(2):148–153.
   PubMed Web of Science ®Google Scholar
• MEDENICA RD, MUKERIEE S, ALONSO K, LAZOVIC G, HUSCHART T: Plasmapheresis combined with interferon: an effective therapy for multiple sclerosis. J. Clin. Apheresis (1994) 9(4):222–227.
   PubMed Web of Science ®Google Scholar
• SORENSEN PS, WANSCHER B, SZPIRT W et al.: Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. Neurology (1996) 46(6):1620–1625.
   PubMed Web of Science ®Google Scholar
• SORENSEN PS, FAZEKAS F, LEE M: Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur. Neurol (2002) 9(6):557–563.
   Web of Science ®Google Scholar
• SORENSEN PS, WANSCHER B, JENSEN CV et al.: Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology (1998) 50(5):1273–1281.
   PubMed Web of Science ®Google Scholar
• VASSILEV T, YAMAMOTO M, AISSAOUI A et al.: Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur. Inonunol. (1999) 29(8):2436–2442.
   Google Scholar
• STANGEL M, TOYKA KV, GOLD R: Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch. Neurol (1999) 56(6):661–663.
   PubMed Web of Science ®Google Scholar
• KISHIMOTO T: The biology of Interleukin-6. Blood (1989) 74(1):1–10.
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis Therapeutics. RA Ruclick, DE Goodkin (Eds), Martin Dunitz, London (1999):309–333.
   Google Scholar
• BERNASCONI NL, TRAGGIAI E, LANZAVECCHIA A: Maintenance of serological memory by polyclonal activation of human memory B cells. Science (2002) 298:2199–2202.
   PubMed Web of Science ®Google Scholar
• ••A valuable paper providing importantinsights on the immunology of B cells.
   Google Scholar
• BIELEKOVA B, MARTIN R: Multiple sclerosis: immunotherapy. Curr. Treat. Options Neurol (1999) 1(3):201–220.
   PubMedGoogle Scholar
• GOBBINI MI, SMITH ME, RICHERT ND, FRANK IA, McFARLAND HF: Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J. Neuroinonunol. (1999) 99(1):142–149.
   PubMed Web of Science ®Google Scholar
• KHAN OA, ZVARTAU-HIND M, CAON C et al.: Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Malt. Scler. (2001) 7(3):185–188.
   PubMed Web of Science ®Google Scholar
• TEN BERGE RI, VAN WALBEEK HK, SCHELLEKENS PT: Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis. Clin. Exp. Inonunol. (1982) 50(3):495–502.
   PubMed Web of Science ®Google Scholar
• MOODY DJ, KAGAN J, LIAO D, ELLISON GW, MYERS LW: Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters. J. Neurainonuna (1987) 14(2):161–173.
   Google Scholar
• LAMERS KJ, UITDEHAAG BM, HOMMES OR, DOESBURG W, WEVERS RA, VON GEEL WI: The short- term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. I Neuro/. Neurosurg. Psychiatry (1988) 51(10):1334–1337.
   PubMed Web of Science ®Google Scholar
• KUZEL TM, ROENIGK HH Jr, SAMUELSON E, ROSEN ST: Suppression of anti-interferon alpha-2a antibody formation in patients with mycosis fungoides by exposure to long-wave UV radiation in the A range and methoxsalen ingestion. J. Natl. Cancer Inst. (1992) 84(2):119–121.
   PubMed Web of Science ®Google Scholar
• RAJAN GP, SEIFERT B, PRUMMER 0, JOLLER-JEMELKA HI, BURG G, DUMMER R: Incidence and in vivo-relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon-alpha 2a combined with acitretin or PUVA. Arch. Dermatol Res. (1996) 288(9):543–548.
   PubMed Web of Science ®Google Scholar
• WILES CM, OMAR L, SWAN AV et aL: Total lymphoid irradiation in multiple sclerosis.' Neurol Neurosurg. Psychiatry (1994) 57(2):154–163.
   Google Scholar